-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Author: Medical team doctors report NMT NMT ENDO compile reports, please do not reprint without authorization.
Introduction: On March 20th, US time (early morning on the 21st, Beijing time), the 2021 American Society of Endocrinology Annual Meeting (ENDO) was officially held.
This conference covers many fields of endocrinology, and many research results have been published.
Let's pay attention to the relevant research progress of "GLP-1RA and breast cancer risk".
Glucagon-like peptide-1 receptor agonist (GLP-1RA) is a new type of diabetes treatment drug developed and marketed in recent years, and it has also been approved for the treatment of obesity in some countries.
Cancer risk is the main focus of the development of drugs to treat obesity and diabetes.
In the randomized controlled trial (RCT) of the Liraglutide (a type of GLP-1RA) development project, subjects receiving active drug therapy had a higher absolute number of breast cancer events.
In order to explore the relevance of the two, Dr.
Giovana Piccoli from the German Gate Hospital in Brazil and others conducted a systematic review and extraction analysis study on "Assessing the Correlation between GLP-1RA and Breast Cancer Risk" in the form of a poster at the 2021 ENDO conference.
It was shown.
The purpose of the study was to evaluate whether patients treated with GLP-1RAs have a higher risk of breast cancer.
Research methods Researchers have searched the relevant research of MEDLINE, Embase, Web of Science and CENTRAL archives, and the deadline is February 8, 2020.
Key words for search include: randomized controlled study, control group containing GLP-1RA active drug or placebo control group, the test population involves overweight, obese, pre-diabetic or diabetic patients, the follow-up period is at least 24 weeks, and at least one case of breast cancer has been reported Or benign breast tumor events.
Researchers extracted research-level data and used ROB2.
0 tools to assess the risk of bias and the quality of evidence within the research.
This study follows the PRISMA reporting guidelines.
The results of the study included 52 trials, 50 of which reported breast cancer events and 11 reported benign breast tumors.
The overall methodological quality is high.
Of the 48267 subjects who received GLP-1RAs treatment, 130 developed breast cancer; there were 40755 subjects in the control group, of which 107 developed breast cancer (RR=0.
98; 95% CI, 0.
76-1.
26).
Subgroup analysis of follow-up time, participant/investigator blinding, and GLP-1RA type found no differences.
There was no significant difference in the risk of benign breast tumors between the two groups (RR=0.
99; 95%CI, 0.
48-2.
01).
Research conclusions This systematic review and extraction analysis study shows that the use of GLP-1RAs to treat obesity and diabetes does not increase the risk of breast cancer in patients.
Introduction: On March 20th, US time (early morning on the 21st, Beijing time), the 2021 American Society of Endocrinology Annual Meeting (ENDO) was officially held.
This conference covers many fields of endocrinology, and many research results have been published.
Let's pay attention to the relevant research progress of "GLP-1RA and breast cancer risk".
Glucagon-like peptide-1 receptor agonist (GLP-1RA) is a new type of diabetes treatment drug developed and marketed in recent years, and it has also been approved for the treatment of obesity in some countries.
Cancer risk is the main focus of the development of drugs to treat obesity and diabetes.
In the randomized controlled trial (RCT) of the Liraglutide (a type of GLP-1RA) development project, subjects receiving active drug therapy had a higher absolute number of breast cancer events.
In order to explore the relevance of the two, Dr.
Giovana Piccoli from the German Gate Hospital in Brazil and others conducted a systematic review and extraction analysis study on "Assessing the Correlation between GLP-1RA and Breast Cancer Risk" in the form of a poster at the 2021 ENDO conference.
It was shown.
The purpose of the study was to evaluate whether patients treated with GLP-1RAs have a higher risk of breast cancer.
Research methods Researchers have searched the relevant research of MEDLINE, Embase, Web of Science and CENTRAL archives, and the deadline is February 8, 2020.
Key words for search include: randomized controlled study, control group containing GLP-1RA active drug or placebo control group, the test population involves overweight, obese, pre-diabetic or diabetic patients, the follow-up period is at least 24 weeks, and at least one case of breast cancer has been reported Or benign breast tumor events.
Researchers extracted research-level data and used ROB2.
0 tools to assess the risk of bias and the quality of evidence within the research.
This study follows the PRISMA reporting guidelines.
The results of the study included 52 trials, 50 of which reported breast cancer events and 11 reported benign breast tumors.
The overall methodological quality is high.
Of the 48267 subjects who received GLP-1RAs treatment, 130 developed breast cancer; there were 40755 subjects in the control group, of which 107 developed breast cancer (RR=0.
98; 95% CI, 0.
76-1.
26).
Subgroup analysis of follow-up time, participant/investigator blinding, and GLP-1RA type found no differences.
There was no significant difference in the risk of benign breast tumors between the two groups (RR=0.
99; 95%CI, 0.
48-2.
01).
Research conclusions This systematic review and extraction analysis study shows that the use of GLP-1RAs to treat obesity and diabetes does not increase the risk of breast cancer in patients.
